MAY 24, 2019 04:11 PM PDT

First PI3K Inhibitor for Breast Cancer

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient’s specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

“For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks.”

It’s important to note that metastatic breast cancer is breast cancer that has reached to other organs in the body most notably the bones, lungs, liver or brain. When breast cancer is hormone-receptor-positive, patients receive anti-hormonal endocrine therapy either alone or in combination with other medicines.

Piqray is a Trademark of the biopharmaceutical company, Novartis

With the efficacy of Piqray and fulvestrant, it can significantly prolong progression-free survival in patients whose tumors had PIK3CA mutation.

Some common side-effects of Piqray include high blood glucose levels, an increase in creatinine, diarrhea, rash, decrease in white blood cell count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in pancreatic enzymes, decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, and hair loss.

Source: FDA

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Fast-Acting Drug For Depression
Many individuals going through depression gain little benefit from treatments whether drugs or talk therapy. Depression represents one of the greatest unme...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
PARP Inhibitors Boost Immune Efficacy
In a recent research study, precision cancer drugs called PARP inhibitors are previously known to boost the immune system were found to spark a powerful im...
JUN 18, 2019
Genetics & Genomics
JUN 18, 2019
The Power and Responsibility of Using CRISPR
      What makes CRISPR so powerful is that it is easy for any molecular or genetic scientist to use, and it works on almost every cell...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Underwater Forest May Bring New Therapeutics
Microbes that produce defensive compounds have contributed to the major source of antibiotics and other therapeutics. However, due to the rise of antibioti...
JUN 18, 2019
Microbiology
JUN 18, 2019
Manuka Honey Kills Cystic Fibrosis Pathogens in Culture
Manuka honey is recognized as a natural antimicrobial agent, and has been used in folk medicines for thousands of years....
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Injectable Hydrogel Recruits Chemotherapeutics to Tumor Site
Targeting tumor cells while avoiding harming healthy tissue remains a growing central challenge in the field of chemotherapeutics. For a while, scientists ...
Loading Comments...